Method for determination of antibodies to viruses of types 1, 3 polyomyelitis in blood serum

FIELD: medicine.

SUBSTANCE: invention relates to methods for determination of antibodies to the virus of type 1, 3 poliomyelitis in the serum, where a killed poliomyelitis virus antigen contained in an inactivated polio vaccine and hemolytic serum are added to the serum in modified complement binding reaction, the samples are maintained, then quantification of oxidase enzymes from hemolysed erythrocytes is performed using tetramethylbenzidine. And the presence of antibodies to polioviruses of types 1 and 3 is determined by the degree of erythrocytes lysis spectrophotometrically by the colour index.

EFFECT: invention provides a possibility of method implementation in any hospital equipped with an ELISA laboratory, preventing the development of outbreaks of poliomyelitis among the population.

2 ex, 2 tbl

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: content of calcium and protein in oral liquid is determined before and after physical load, as well as a day after physical load. Recovery of content of calcium ions and protein in oral liquid after physical load to initial values is considered to be a criterion of total recovery of athlete's-volleyball player's organism, with evaluating time interval, required for said process.

EFFECT: invention makes it possible to determine reserve abilities of organism and its adaptability in athletes-volleyball players to physical load.

2 dwg, 4 tbl

FIELD: chemistry.

SUBSTANCE: claimed is a portative analyser for the analysis of a biological fluid sample, which contains a body with a magazine, which has units for placing applied for the analysis diagnostic strips or test-strips, possessing a zone for a biological fluid, an analysing device with a slot-like receiver for the applied diagnostic strip or the test-strip, provided with electric contacts from one end, and an indicator device for the display of not fewer than one analysis result. The body from the back part side is made with a lowering, which forms a flat surface, on which along the body or transversely to it made are projections, dividing the flat surface of the lowered part into units for the placement of the diagnostic strips or test-strips and forming the magazine, located parallel in not fewer than one line. The units are closed with a demountable or an openable lid, which is a part of the body. 2 other versions of the portative analyser are also described.

EFFECT: extension of exploitation properties and increase of efficiency.

25 cl, 12 dwg

FIELD: medicine.

SUBSTANCE: spontaneous glow, an induction period and a fast flash amplitude over a period of 5 minutes of recording are measured, and an adaptation risk ratio (ARR) is calculated by formula: ARR=Cn-A/π, wherein: ARR is the adaptation risk ratio; Cn is the spontaneous glow; A is the fast flash amplitude; π is the induction period. If the ARR is 0.066-3.85 standard units, the adaptation is considered to be satisfactory, or compensated; the ARR falling within the range of 3.88-6.5 standard units stands for an adaptation tension; provided the ARR ranges 6.6-9.5 standard units, the adaptation is stated as unsatisfactory, whereas the ARR of 9.6 standard units and more shows an adaptation failure.

EFFECT: more accurate assessment ensured by determining adaptation-based grouping criteria.

1 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and can be applicable for measuring catecholamines and their metabolites in complex array-based objects, including water-soluble, without additional sample preparation. A method is implemented by varying a principal analytical signal shaping and measurement network with the signal recorded in a sensitive biosensor layer; that is followed by a solid-phase fluorescence. The biosensor action is based on enzymatic derivatisation of catecholamines and their metabolites with organic amines (o-phenylene diamine, ethylene diamine) to form quinoxaline derivatives fluorescing in the range of 450-550 nm. The indicator test components are immobilised in the sensitive layer on the biosensor surface; that results in forming and recording the fluorescent signal on the solid surface directly in the reflection mode. The peak fluorescent signal intensity is generated when using a derivatizing agent presented by o-phenyldiamine and performing a process in the horseradish peroxidise concentration of 10-25 nM; in the hydrogen peroxide concentration of 250-500 mcM; in the o-phenylene diamine concentration of 50-100 mcM; in the concentration of catecholamines and their metabolites of 5-2000 nM. Buffer is phosphate buffer 5 mM of pH 9.5-10.0. The sensitive biosensor layer represents a double-layer film {chitosan - o-phenylene diamine/chitosan - peroxidase} applied as a smooth layer on the surface of a glass plate (14×40 mm).

EFFECT: invention provides the simple and sensitive measurement of catecholamines and their metabolites in the objects, which used to be difficult or impossible to analyse using optical detection method for instrumental reasons because the real object has a harmful influence, while the biosensors are insufficiently sensitive and reproducible.

4 cl, 4 dwg

FIELD: medicine.

SUBSTANCE: substance of the invention consists in simulating acute mesenteric ischemia in rats followed by measuring the lymphocyte count in the central venous blood, and decreasing the measured count by more than 80% from average normal values enables diagnosing intestinal necrosis.

EFFECT: higher accuracy and simplifying the diagnosis of intestinal necrosis accompanying mesenteric ischemia.

3 ex

FIELD: medicine.

SUBSTANCE: invention represents a method of differential diagnostics of chronic viral hepatitis and fatty liver disease in patients with dyslipidemia syndrome, consisting in the following: activity of the glutathione reductase antioxidant system enzyme (GLR), which is estimated by a spectrophotometric method, is determined in the patient's blood serum, and if GLR value is lower or equals 14.6 mcmol/l/min, the fatty liver disease is diagnosed, if GLR concentration is higher than 14.6 mcmol/l/min, chronic viral hepatitis is diagnosed.

EFFECT: reduction of trauma, increase of availability and simplicity of realisation with high sensitivity, specificity and effectiveness.

4 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to oncology. A combined scattering spectroscope is used to record a spectral series of the new growth and healthy tissue. A working portion of the spectroscope is placed directly above the examined region at 3-4 mm. Recording the spectra is followed by performing the statistical analysis of the results on a personal computer. Analysing involves identifying two phase signs that are a relation of peak intensities of the combined scattering in the bandwidths 1300-1340 cm-1 and 1640-1680 cm-1 to the bandwidth 1430-1470 cm-1. The combined scattering spectroscopic data obtained by each measurement are presented as a point on a phase plane. The point is found in one of three regions of the phase plane. According as which of the three regions of the plane comprises the point, either melanoma, or basal cell or squamous cell cancer, or no skin growths is diagnosed in the patient.

EFFECT: method enables obtaining objective data enabling differentiating various types of the skin growths, that provides high accuracy of the pre-operative diagnosis.

1 ex

FIELD: medicine.

SUBSTANCE: child's lachrymal fluid is examined to measure activity of γ-glutamyltransferase, and if the measured value is more than 11 Unit/l, the disease is diagnosed.

EFFECT: detecting myopia in the pre-school children when it is impossible to test the visual acuity according to the Orlova's chart.

4 ex

FIELD: biotechnologies.

SUBSTANCE: invention refers to a method of simultaneous determination of zinc cation concentration and zinc and copper cation ratio in blood serum, involving use of dithizone solution in carbon tetrachloride as the main reactant, incubation at room temperature in alkali medium, organic phase removal and colorimetry of colloid solutions of blood serum sample and standard solution at 535 nm, zinc cation concentration calculation, colorimetry of colloid solutions of blood serum sample and standard solution at 435 nm and molar ration calculation for zinc and copper cations.

EFFECT: determination of zinc cation concentration in blood serum together with zinc and copper cation ratio in the same sample without additional reactants.

4 ex

FIELD: chemistry.

SUBSTANCE: method is carried out as follows: crushing biological material containing O-(2,3-dihydro-2,2-dimethyl-7-benzofuranyl)-N-methyl carbamate, treating the material three times with a mixture of ethyl acetate and acetone taken in ratio of 1:1 by volume, each time for 30 minutes; merging the obtained extracts; evaporating the extractant; dissolving the residue in acetonitrile; diluting the obtained solution with water in ratio of 1:4 by volume; extracting with ethyl acetate twice with volume ratio of water to the organic phase of 1:1 at each extraction step; merging the ethyl acetate extracts; evaporating to a dry residue; dissolving the residue in acetonitrile; adding water to the solution to achieve volume ratio of acetonitrile to water of 4:6; adding the obtained solution to a Silasorb S18 sorbent column; carrying out a chromatographic process using a two-component mobile phase of acetonitrile-water in ratio of 4:6 by volume; merging eluate fractions containing O-(2,3-dihydro-2,2-dimethyl-7-benzofuranyl)-N-methyl carbamate; evaporating the eluent; dissolving the residue in methanol and performing determination with a physical-chemical method, which is chromatography-mass spectrometry, in a DB-5 MS EVIDEX capillary column with length of 25 m and inner diameter of 0.2 mm with a stationary phase which is 5% phenyl-95% methylpolysiloxane, with film thickness of the stationary phase of 0.33 mcm, using a helium carrier gas fed at a rate of 0.6 ml/min, and a mass-selective detector operating in electron impact mode, the initial thermostat temperature of the column being 70°C; maintaining said temperature for 3 min, then raising the temperature from 70°C to 290°C at a rate of 20°C/min; maintaining the final temperature of the column for 16 min; temperature of the injector is 250°C, temperature of the quadrupole is 150°C, temperature of the detector interface is 300°C; detecting strength of the signal resulting from charged particles formed when bombarding the analysed substance coming from the capillary column and falling into an ion source with an ionising electron beam with energy of 70 eV; recording the mass spectrum on the full ion current and calculating the amount of O-(2,3-dihydro-2,2-dimethyl-7-benzofuranyl)-N-methyl carbamate from the area of the chromatographic peak.

EFFECT: high sensitivity.

4 tbl, 3 ex

FIELD: medicine, analytical biochemistry.

SUBSTANCE: invention relates to laboratory methods of investigations. Method involves sampling specimen from patient to be inspected, extraction of serotonin and histamine from a specimen, chromatography of extract and determination of concentration of serotonin and histamine by the fluorescence intensity value. Saliva is used as biological fluid. Saliva by volume 1 ml is extracted with 4 ml of 1 N hydrochloric acid solution, 2 g of anhydrous potassium carbonate and 5 ml of mixture of butanol and chloroform in the ratio 3:2 are added, extract is shaken up and centrifuged. Organic phase (4 ml) is sucked off from extract and passed through chromatography column (diameter is 3 mm, height is 16 mm) filled with ion-exchange resin KB-4 or KB-4P-2 or Bio Rex-70 in H+-form, size of granules is 0.1 ± 0.02 mm. Histamine is eluted with 4 ml of 0.1 N hydrochloric acid at the rate of eluting solution 0.4 ml/min. Histamine concentration is determined by reaction with ortho-phthalic aldehyde dissolved in ethanol. Serotonin concentration is determined by reaction with ninhydrin in organic passed through column. Method provides assaying the saliva concentration of serotonin and histamine with high precision.

EFFECT: improved assay method.

FIELD: medicine.

SUBSTANCE: method involves studying blood samples with venous blood mixed with vital stain like methylene blue. Degree of vital stain absorption by erythrocytes is determined by applying photocolorimetry. The value drop being more than 25%, extracorporal detoxication is to be predicted as ineffective.

EFFECT: simplified method.

6 tbl

FIELD: medicine, infectology.

SUBSTANCE: one should detect the level of terminal stable metabolites of nitrogen oxide (NOx) in whole blood. At its value ranged 39.6-86.0 mcM/l one should evaluate hemorrhagic fever accompanied with renal syndrome (HFRS) of average severity, at NOx value ranged 86.7-141.5 mcM/l - severe form of HFRS and at its values ranged 88.2-128.6 mcM/l at the background of pronounced clinical picture - as complicated disease flow. The method enables to shorten the terms for carrying out the assays.

EFFECT: higher accuracy of evaluation.

3 ex, 1 tbl

FIELD: medicine, biochemistry.

SUBSTANCE: in blood serum one should detect the level of lactoferrin and biliary acids. At their ratio being equal to 5-17 it is necessary to detect chronic hepatitis of high activity.

EFFECT: higher accuracy of detection.

3 ex

FIELD: medicine, dermatology, clinical laboratory diagnostics.

SUBSTANCE: the present method deals with detecting the focus of neutrophilic phagocytic activity lesion in capillary blood. At the values of cells' capacity to phagocytosis in percentage and phagocytic number on the 10th d of therapy being below 20% and 3.3, correspondingly one should evaluate therapeutic efficiency to be low, if it is above 40% and 4.0, correspondingly - as high.

EFFECT: higher accuracy of evaluation.

2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: method involves studying blood serum, processing obtained data and setting disease diagnosis. The study is carried out by preparing dried blood serum sample as suspension in Vaseline oil and doing the infrared spectroscopy analysis in the bandwidth of 120-1000 cm-1 and determining absorption strip peak heights having maximum at 1180; 1165; 1160; 1150; 1130; 1070; 1025 cm-1 and then calculating the following two ratio groups, the first of which is ratio of peak height with maximum at 1165 cm-1 to 1150 cm-1; 1160 cm-1 to 1130 cm-1; 1070 cm-1; 1025 cm-1. The second group has ratio peak having maximum at 1165 cm-1 to 1160 cm-1; 1180 cm-1 to 1130 cm-1; 1065 cm-1; 1070 cm-1. The obtained three-dimensional distribution of the first group is projected to frontal plane for calculating two-dimensional coordinates and comparing to flat reference diagnostic images of hepatic pathologies and to a normal reference diagnostic image represented as flat polygons which boundaries are given by the following values. The norm is represented by X(-2.3;2.0;4.0;4.0) and Y(1.6;0.8;0.8;1.6), respectively. Oncology is represented by X(1.7;1.7;0.0;0.0) and Y(1.9;1.25; 1.25;1.9). Hepatites are represented by X(1.9;2.2;1.8;1.4 and 1.9;1.8;4.0) and Y(1.9;1.9; 0.5;0.5 and 08;0.5;0.8). Cirrhosis is represented by X(1.9;2.6;1.4) and Y(1.6;0.8;0.4). Diseases are differentiated by interpreting point position within particular area. Three-dimensional distribution of the second group is projected to frontal plane and compared to diagnosis images of pathology and norm. Coordinate values of the second group are as follows: norm - X(1.8;2.9;2.5;1.5), Y(2.7;2.0;1.2;1.6); oncological cases - X(0.27;0.67;0.63), Y(0.27;0.67;0.3); hepatitis - X(1.5;2.5;2.4;1.2), Y(1.6;1.2;0.2;0.9); cirrhosis - X(1.1;0.9;0.9). Final diagnosis of pathology is set when particular data values belong to the corresponding pathology zone in both cases.

EFFECT: high accuracy of diagnosis.

FIELD: medicine.

SUBSTANCE: method involves studying biological material by applying infrared spectroscopy techniques. The obtained data are processed and diagnosis is set. Blood serum is used as the biological material. The study is carried out by preparing dried blood serum sample as suspension in Vaseline oil and doing the infrared spectroscopy analysis in the bandwidth of 120-1000 cm-1 and determining absorption strip peak heights having maximum at 1170; 1165; 1160; 1150; 1140; 1060; 1050; 1040; 1025 and then calculating the following ratio values like peak height with maximum at 1160 cm-1 to 1140 cm-1; 1165 cm-1 to 1150 cm-1; 1040 cm-1 to 1025 cm-1. The obtained distribution of this group is projected to frontal plane for calculating two-dimensional coordinates and comparing to flat reference diagnostic images of prostate pathologies and to a normal reference diagnostic image represented as flat polygons which boundaries are given by the following values. The norm is represented by X(-1.15;-0.9;0.45;0.0;-0.65) and Y(0.99;4.2;0.9;0.46), respectively. Pathology by X(-1.15;-1.15;0.35;0.0;0.65) and Y(0.99;-0.03; 0.48;0.09;0.46). The norm and pathology are differentiated. Additional mathematical processing is carried out on infrared spectra of blood serum samples of patients belonging to pathology image according to parameter values. First of all, three-dimensional distribution is calculated as peak having maximum at 1160 cm-1 to one having maximum at 1150 cm-1; 1170; 1160 cm-1; 1160 cm-1 to 1025 cm-1. It is projected then to frontal plane and compared to diagnosis images of prostate adenoma and images of prostate carcinoma. The second group relationships the following values are used: oncological cases - X(0.28;0.77;1.24;0.96), Y(0.75;0.46;-0.13;-0.02); adenoma - X(0.28;1.24;2.21;1.24;0.77), Y(0.75;1.24;-0.12;-0.13;0.46). Differential diagnosis of pathologies is set by interpreting point position within particular pathology image.

EFFECT: high accuracy of differential diagnosis.

FIELD: medicine.

SUBSTANCE: method involves determining mean cytochemical coefficient of lipid accumulation in peripheral blood leukocytes in conditional units before beginning therapy application (MCC1) and in 2-3 or 5-6, or 10-12, or 20-24 months of therapy application (MCC2). Therapy effectiveness coefficient is calculated in conditional units from formula K= MCC2/MCC1. The value being equal to or greater than 1, leprosy therapy is predicted to be effective.

EFFECT: simplified prognosis method.

1 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves determining infrared radiation absorption coefficient in blood plasma in bandwidth of 1543-1396 cm-1. The infrared radiation absorption coefficient is determined in %. The value being equal to 29.7±1.1%, catarrhal cholecystitis is diagnosed. The value being 26.4±1.4%, phlegmonous cholecystitis is diagnosed. The value being 21.2±1.8%, gangrenous cholecystitis is diagnosed. The value being equal to 18.6±0.5%, gangrenous perforated cholecystitis case is diagnosed. The value in norm is equal to 32.4±0.8%.

EFFECT: high accuracy and specificity of diagnosis.

FIELD: medicine.

SUBSTANCE: method involves pouring venous blood treated with heparin into five conic test-tubes in the amount of 0.1 ml. The first three of them contain 0.1 ml of non-colored latex suspension with particle size of 1.5 mcm, the fourth one contains 0.1 ml of medium 199 and 0.1 ml of 0.1% aqueous solution of tetrazole nitro blue, the fifth one contains .1 ml of latex suspension and 0.1 ml of 0.1% aqueous solution of tetrazole nitro blue. The first test-tube is incubated in thermostat for 5 min at37°C, the second one for 30 min, the third one for 1 h, the fourth and the fifth one for 40 min. Smears are prepared from 0.2 ml of incubation mixture on glasses and dried at 37°C, fixed in burner flame, stained with 0.1% aqueous solution of tetrazole nitro blue, repeatedly dried and studied with microscope under immersion with magnification of 90x10. Test results are evaluated from absorption activity in phagocytosis reactions in determining the number of phagocytes, phagocytic number, phagocytic integral index and phagocytosis rate values. Tetrazole nitro blue test response is determined by counting formazan-positive cell number, calculating cytochemical activity index and tetrazole nitro blue test stimulation index.

EFFECT: accelerated test; high accuracy and low cost of examination.

1 dwg, 3 tbl

Up!